Day 2: ACCESS Programmes Congress

Conference Agenda


Expanded Access Programmes - Day 2

Day 2: Thursday 2nd December 2021


  • Deep-dive into the reality of healthcare access around the world
  • Streamlining the process and navigating early access regulations globally
  • What does the future of health access look like? The interconnected ecosystem where all healthcare stakeholders work together
  • How MAPs fit with an orphan launch strategy
  • How to design them effectively taking all stakeholders into account
  • Best practice in implementation and management
  • When does a MAP end?



  • Compassionate use has been increasingly associated with a patient’s right to try
  • Public knowledge of the clinical trials process with specific reference to innovative stem cell treatments
  • Need for a commitment to support vulnerable patients
  • Strengthen awareness among the public about the substantial boundary that differentiates experimental therapies from unproven therapies
  • Companies should anticipate the need for EA and should have a written policy
  • The policy should be available to the person entitled to expanded access
  • Companies must be accountable to the patients sending expanded access requests
  • Sharing of data analysis is crucial for improvement


  • Interaction between life science companies and healthcare providers could foster the development of new medicines which will ultimately benefit patients.
  • Would this enhance technological innovation, fosters knowledge creation, aid disease control, and reduces polypharmacy issues?
  • Guidelines to help professionals navigate the opposing explanations of interactions with pharmaceutical companies
  • Alternative access schemes offer flexibility to policymakers but often lack transparency and clear rules.
  • The uncertainties allow for dynamic responses to weaknesses in the main drug approval and reimbursement systems
  • Challenges facing the reimbursement system
  • Understanding different payer strategies currently in place
  • The importance of patient advocacy in providing much-needed information on EAP’s available for patients
  • Collaborating with one another to enable a much richer understanding of patient needs
  • Patient groups’ importance in working with health authorities to advance policies that accelerate patient access to investigational medicines
  • Creating a state of the art payer engagement strategies to address challenges in pricing and reimbursement
Scroll to Top